Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- MHLW Re-Stresses Caution over Use of EGFR TKIs in Opdivo-Treated Patients
September 7, 2016
- Barcode Labeling Increasing in Anticipation of Mandatory Use in 2021: MHLW Survey
September 6, 2016
- 6 National Centers Log Generic Use Rate of Average 73.8% in FY2015
September 6, 2016
- MHLW Issues Notification on Partial Revision of Rules for New Barcode Labeling to Be Required from April 2021
September 6, 2016
- PMDA to Host Int’l Seminars in 2017 under Asian Training Center Initiative
September 5, 2016
- G7 Health Ministers to Discuss AMR Measures at Upcoming Kobe Confab
September 5, 2016
- METI Seeks 7.2 Bil. Yen for Drug Discovery, 3.5 Bil. for Regenerative Medicine
September 2, 2016
- Panel OKs Iridosteresis, 7 Other Illnesses as Designated Intractable Diseases
September 1, 2016
- Govt Health Promotion Taskforce Seeks 152.8 Billion Yen for AMED
September 1, 2016
- “Untreated” Erased from Viekirax’s Add’l Indication: Sept. 9 Panel Meeting
August 31, 2016
- Lilly Drops Listing of Taltz amid Pricing Fuss, Wants to Deliver Drug without Restrictions
August 31, 2016
- MHLW Panel to Discuss Keytruda on Sept. 9, Listing Expected as Early as November
August 30, 2016
- MHLW Unveils FY2017 Budget Request, 105.8 Bil. Yen Sought for Healthcare Innovation
August 29, 2016
- MHLW Requests Extension of R&D Tax Credit for “High-Level Investment”
August 29, 2016
- MHLW OKs RCC Indication for Opdivo, Approval Changes to Other Drugs
August 29, 2016
- AZ’s Ticagrelor, BI’s Triple Combo to Take Another Stab to Clear MHLW Committee
August 26, 2016
- MHLW Advisory Committee to Review Reversal Agent for Prazaxa on Sept. 7
August 26, 2016
- MHLW Grants Orphan Status to Crizotinib, 3 Other Drugs
August 26, 2016
- Innovative Drugs Are Not “Villain,” Kamoya Laments
August 25, 2016
- Chuikyo Subcommittee Effectively Kicks Off Debates on FY2018 Reform, with Focus on Pricy Meds
August 25, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…